Recall the Draft? FDA’s Final Guidance on Mandatory Cosmetic Recalls Looks Familiar

This final guidance closes out the rulemaking-adjacent process that the FDA began with its December 2025 draft, which we covered in our prior alert.

What Changed From the Draft

In short: nothing of substance. The FDA received seven comments on the draft, which it characterized as broadly supportive, with some requesting clarification of issues discussed in the draft. After considering those comments, the FDA elected to publish the guidance as drafted.

Substantive Recap

As detailed in our prior alert, MoCRA authorizes the FDA to order a mandatory recall of a cosmetic where (1) the agency determines there is a reasonable probability that the product is adulterated or misbranded and that use of or exposure to it will cause serious adverse health consequences or death (SAHCOD), and (2) the company declines to voluntarily cease distribution or recall the product after being given the opportunity to do so. The authority runs against the “responsible person,” i.e., the manufacturer, packer, or distributor whose name appears on the label. 

The final guidance reiterates the FDA’s process for ordering a mandatory recall, as provided in the draft guidance and covered in our prior alert:

• The FDA must first offer, in writing, an opportunity to voluntarily cease distribution and recall. 
• If that offer is declined, the FDA may order an immediate cessation of distribution, followed by an informal hearing within 10 days to address whether adequate evidence exists to justify the order.
• After the hearing, the FDA may vacate, continue, or amend the order to require a recall. 

Only the commissioner may order or vacate a mandatory recall, and that authority is non-delegable. The FDA will publish a press release and may post a product image, and refusal to comply is a prohibited act exposing firms to injunction and criminal prosecution. The FDA continues to expect that most cosmetic recalls will remain voluntary.

What It Means

Because the FDA declined to add the requested clarifications, open questions remain.

The guidance still does not say how much time a company will have to act voluntarily before the FDA moves to an order — only that the responsible person must act “within the time and manner prescribed by FDA, if so prescribed.” Likewise, whether exposure will cause SAHCOD remains a case-by-case judgment, informed by evidence including inspection observations, sample and environmental swab analyses, epidemiological data, the presence of vulnerable populations, serious adverse event reports, consumer and trade complaints, and a firm’s failure to recall voluntarily.

Key Takeaways for Cosmetic Companies

• Confirm Responsibilities: Confirm who is the labeled “responsible person” across all brands and SKUs, including private-label and distribution arrangements, and allocate recall responsibilities and costs in supply and distribution agreements.
• Strengthen cGMP Compliance: Maintain robust compliance with good manufacturing practice requirements.
• Substantiate Safety: Adequately substantiate the safety of each cosmetic product and ingredient.
• Validate Labeling: Confirm cosmetic labeling complies with statutory and regulatory requirements.
• Strengthen Adverse Event-Related Processes: Bolster serious adverse event monitoring and complaint-handling procedures — both adverse event data and consumer and trade complaints are evidence the FDA stated that it may weigh when considering whether to institute a mandatory recall.
• Update Recall Procedures: Update recall plans for the compressed timeline, including the written FDA offer, a short window to act voluntarily, and a 10-day hearing — with pre-drafted supply chain and public notices and clear escalation protocols.

ArentFox Schiff will continue to closely monitor additional updates on MoCRA compliance.

If you are interested in more information about MoCRA or are seeking guidance on any cosmetic-related requirements, please contact the authors.